Roche, GSK lung-cancer drug candidates show promise in China
J.P. Morgan analysts said clinical-trial data in China-only studies look strong for lung-cancer candidates from Roche and GSK’s partners.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.